Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality - Poll - MDSpire

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

  • By

  • Joaquín Martínez-López

  • María-Victoria Mateos

  • Cristina Encinas

  • Anna Sureda

  • José Ángel Hernández-Rivas

  • Ana Lopez de la Guía

  • Diego Conde

  • Isabel Krsnik

  • Elena Prieto

  • Rosalía Riaza Grau

  • Mercedes Gironella

  • María Jesús Blanchard

  • Nerea Caminos

  • Carlos Fernández de Larrea

  • María Alicia Senin

  • Fernando Escalante

  • José Enrique de la Puerta

  • Eugenio Giménez

  • Pilar Martínez-Barranco

  • Juan José Mateos

  • Luis Felipe Casado

  • Joan Bladé

  • Juan José Lahuerta

  • Javier de la Cruz

  • Jesús San-Miguel

  • October 19, 2020

  • 0 min

Share

Original Source(s)

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

  • by Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, Anna Sureda, José Ángel Hernández-Rivas, Ana Lopez de la Guía, Diego Conde, Isabel Krsnik, Elena Prieto, Rosalía Riaza Grau, Mercedes Gironella, María Jesús Blanchard, Nerea Caminos, Carlos Fernández de Larrea, María Alicia Senin, Fernando Escalante, José Enrique de la Puerta, Eugenio Giménez, Pilar Martínez-Barranco, Juan José Mateos, Luis Felipe Casado, Joan Bladé, Juan José Lahuerta, Javier de la Cruz, Jesús San-Miguel

  • October 19, 2020

Related Content

SARS-CoV-2 infection complicated by acute longitudinally extensive transverse myelitis and pulmonary embolism: a case report

Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.